NAUT

Nautilus Biotechnology, Inc. NASDAQ Listed Aug 7, 2020

Healthcare ·Biotechnology ·US · nautilus.bio

$2.88

Mkt Cap $366.0M

52w Low $0.62 61.2% of range 52w High $4.31

50d MA $2.90 200d MA $1.82

P/E (TTM) -5.7x

EV/EBITDA -5.0x

P/B 2.2x

Debt/Equity 0.2x

ROE -39.5%

P/FCF -4.7x

RSI (14) —

ATR (14) —

Beta 0.99

50d MA $2.90

200d MA $1.82

Avg Volume 303.1K

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

SIC Code

3826

CIK (SEC)

1808805

Phone

206 333 2001

2701 Eastlake Avenue East · Seattle, WA 98102 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 28, 2026	BMO	-0.14	-0.12	+17.2%	2.57	+7.8%	+0.8%	-3.5%	+5.2%	+2.7%	+7.0%	—
Feb 26, 2026	BMO	-0.14	-0.11	+21.4%	2.89	+4.5%	-16.3%	+0.0%	-4.1%	+3.9%	+8.7%	—
Oct 27, 2025	BMO	-0.15	-0.11	+26.7%	1.22	+0.0%	+10.7%	+5.9%	-1.4%	+0.0%	-5.7%	—
Jul 31, 2025	BMO	-0.15	-0.12	+22.6%	0.76	+5.1%	+0.0%	+0.6%	-3.0%	+1.3%	+4.9%	—
Apr 29, 2025	BMO	-0.14	-0.13	+7.1%	0.68	+2.9%	+8.0%	-6.2%	-0.5%	-1.1%	+1.2%	—
Feb 26, 2025	BMO	-0.16	-0.14	+12.5%	1.47	+0.0%	-2.7%	-18.2%	+11.1%	-4.6%	-2.4%	—
Oct 29, 2024	BMO	-0.17	-0.13	+23.5%	2.81	-4.6%	-1.4%	-4.3%	-1.9%	+0.4%	-1.5%	—
Jul 30, 2024	BMO	-0.16	-0.14	+12.5%	2.74	+0.0%	-2.6%	+1.5%	-7.4%	-3.6%	-6.6%	—
Apr 30, 2024	BMO	-0.16	-0.15	+6.2%	2.57	+3.1%	-1.2%	+9.4%	-4.0%	+0.7%	+4.8%	—
Feb 28, 2024	BMO	-0.16	-0.14	+12.5%	2.94	-4.8%	-4.8%	-3.9%	+1.1%	-1.1%	-3.0%	—
Oct 31, 2023	BMO	-0.18	-0.13	+27.8%	2.34	+0.4%	+9.4%	+0.0%	+5.1%	+6.7%	-14.6%	—
Aug 2, 2023	BMO	-0.17	-0.13	+23.5%	3.15	-4.8%	-2.2%	+1.9%	+1.6%	-5.0%	+2.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 27	Guggenheim	Maintains	Buy → Buy	—	$2.42	$2.42	+0.0%	+0.0%	-4.1%	+3.9%	+8.7%	-6.9%
Dec 5	Goldman Sachs	Downgrade	Neutral → Sell	—	$2.23	$2.20	-1.3%	-13.9%	+11.5%	+1.4%	-2.8%	-1.4%
Aug 3	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$3.08	$3.08	+0.0%	+1.9%	+1.6%	-5.0%	+2.6%	-0.3%
Aug 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$2.82	$2.88	+2.1%	+0.4%	-0.4%	+4.3%	-1.0%	-2.4%
Aug 3	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$2.82	$2.88	+2.1%	+0.4%	-0.4%	+4.3%	-1.0%	-2.4%
Jul 14	Goldman Sachs	Maintains	Neutral → Neutral	—	$2.87	$2.85	-0.7%	-4.9%	+0.0%	-4.4%	+6.1%	+3.2%
Apr 13	Goldman Sachs	Maintains	Neutral → Neutral	—	$4.19	$4.27	+1.9%	-0.7%	-2.6%	-3.5%	+1.0%	+1.5%
Jan 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.85	$4.90	+1.0%	-1.4%	-1.0%	+1.5%	+0.0%	-1.7%
Nov 2	Cowen & Co.	Maintains	Outperform → Outperform	—	$5.44	$5.71	+5.0%	+7.2%	+0.2%	-2.2%	-1.9%	-0.4%
Aug 4	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.65	$7.56	-1.2%	-2.1%	+10.1%	-9.3%	+6.7%	-5.0%
Jul 13	Jefferies	Maintains	Buy → Buy	—	$10.00	$10.16	+1.6%	-2.0%	-3.4%	-2.7%	-1.0%	-0.1%

Data updated apr 26, 2026 2:16pm · Source: massive.com